AC Immune receives $4 million grant for Parkinson's drug trial extension
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
June 11, 2026 7:00 AM EDTAC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinsons Disease
Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 yearsFinal data from Part 1 of VacSYn trial expected in H2 2026Lausanne, Switzerland, June 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision... More
